urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

Latest news

Keytruda gains NICE clearance in first line bladder cancer

Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s treatment within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in ... Pembrolizumab is already
Another Tecentriq win for Roche as Avastin combo boosts survival

Tecentriq is currently approved for previously-treated NSCLC patients and also as a second-line therapy for metastatic urothelial carcinoma, a form of bladder cancer.
NICE says OK to Keytruda for bladder cancer via the CDF

metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. ... Louise Houson, UK managing director for MSD, said: “MSD is really pleased that NICE has recommended pembrolizumab for eligible patients with advanced
MSD’s Keytruda wins bladder cancer indication in Japan

The pharma giant ’s blockbuster has gained a new indication to treat patients with previously treated urothelial carcinoma (UC) that is unresectable with radical surgery and whose disease has progressed following ... chemotherapy. Dr Roy Baynes,
Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

The drug is already approved as a treatment for rare cancer Merkel cell carcinoma and as a second-line therapy for bladder cancer (metastatic urothelial carcinoma), but Pfizer and Merck are

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Sudler London - Senior Medical Writer: Competitive

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director or Senior Account Director: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Market Access Consultant - Greater Manchester: Negotiable

Account Manager: Negotiable

Sudler London - Account Director: Competitive

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Medical Writer - Creative and Scientific Projects: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Healthcare PR Director: £100, 000 – £120, 000 benefits

Associate Scientific Director: Salary TBC

Healthcare PR Senior Account Manager: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Graduate Scientific Editor: DOE

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....